The landscape of neurology biomarkers has evolved significantly in recent years, affording new clinical insights that are ...

TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...

For those on the drug for 24 months, there was also a dose-dependent reduction in neurofilament light chain (NfL) protein, another HD biomarker. When it came to functional outcomes, the results ...

medfak.gu.se BACKROUND Pathological tau protein concentrations in CSF are found in both Alzheimer's disease (AD) and frontotemporal dementia (FTD), but studies on brain tissue have suggested that the ...

asDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden ...